Addex Therapeutics Ltd – Product Pipeline Review

Global Markets Direct’s, ‘Addex Therapeutics Ltd – Product Pipeline Review – 2016’, provides an overview of the Addex Therapeutics Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Addex Therapeutics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Addex Therapeutics Ltd

The report provides overview of Addex Therapeutics Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Addex Therapeutics Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Addex Therapeutics Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Addex Therapeutics Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Addex Therapeutics Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Addex Therapeutics Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Addex Therapeutics Ltd Snapshot 6

Addex Therapeutics Ltd Overview 6

Key Information 6

Key Facts 6

Addex Therapeutics Ltd - Research and Development Overview 7

Key Therapeutic Areas 7

Addex Therapeutics Ltd - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Addex Therapeutics Ltd - Pipeline Products Glance 15

Addex Therapeutics Ltd - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Addex Therapeutics Ltd - Early Stage Pipeline Products 17

IND/CTA Filed Products/Combination Treatment Modalities 17

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Addex Therapeutics Ltd - Drug Profiles 20

dipraglurant IR 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

dipraglurant ER 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ADX-71441 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ADX-71743 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ADX-88178 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ADX-92639 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule to Inhibit FSHR/LHR For Sex Hormone Dependent Tumors 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ADX-90125 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ADX-95477 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecule to Antagonize FSH Receptor for Women's Health 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecules to Agonize TRKB for Alzheimer’s Disease 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Modulate mGlu3 Receptor for CNS Disorders 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Addex Therapeutics Ltd - Pipeline Analysis 39

Addex Therapeutics Ltd - Pipeline Products by Target 39

Addex Therapeutics Ltd - Pipeline Products by Route of Administration 41

Addex Therapeutics Ltd - Pipeline Products by Molecule Type 42

Addex Therapeutics Ltd - Pipeline Products by Mechanism of Action 43

Addex Therapeutics Ltd - Recent Pipeline Updates 44

Addex Therapeutics Ltd - Dormant Projects 51

Addex Therapeutics Ltd - Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

ADX-10059 52

ADX-10061 52

ADX-71943 52

Addex Therapeutics Ltd - Company Statement 53

Addex Therapeutics Ltd - Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

List of Tables

Addex Therapeutics Ltd, Key Information 6

Addex Therapeutics Ltd, Key Facts 6

Addex Therapeutics Ltd – Pipeline by Indication, 2016 8

Addex Therapeutics Ltd – Pipeline by Stage of Development, 2016 11

Addex Therapeutics Ltd – Monotherapy Products in Pipeline, 2016 12

Addex Therapeutics Ltd – Out-Licensed Products in Pipeline, 2016 13

Addex Therapeutics Ltd – Out-Licensed Products/ Combination Treatment Modalities, 2016 14

Addex Therapeutics Ltd – Phase II, 2016 15

Addex Therapeutics Ltd – Phase I, 2016 16

Addex Therapeutics Ltd – IND/CTA Filed, 2016 17

Addex Therapeutics Ltd – Preclinical, 2016 18

Addex Therapeutics Ltd – Discovery, 2016 19

Addex Therapeutics Ltd – Pipeline by Target, 2016 40

Addex Therapeutics Ltd – Pipeline by Route of Administration, 2016 41

Addex Therapeutics Ltd – Pipeline by Molecule Type, 2016 42

Addex Therapeutics Ltd – Pipeline Products by Mechanism of Action, 2016 43

Addex Therapeutics Ltd – Recent Pipeline Updates, 2016 44

Addex Therapeutics Ltd – Dormant Developmental Projects,2016 51

Addex Therapeutics Ltd – Discontinued Pipeline Products, 2016 52

Addex Therapeutics Ltd, Subsidiaries 55

List of Figures

List of Figures

Addex Therapeutics Ltd – Pipeline by Top 10 Indication, 2016 8

Addex Therapeutics Ltd – Pipeline by Stage of Development, 2016 11

Addex Therapeutics Ltd – Monotherapy Products in Pipeline, 2016 12

Addex Therapeutics Ltd – Out-Licensed Products in Pipeline, 2016 13

Addex Therapeutics Ltd – Pipeline by Top 10 Target, 2016 39

Addex Therapeutics Ltd – Pipeline by Route of Administration, 2016 41

Addex Therapeutics Ltd – Pipeline by Molecule Type, 2016 42

Addex Therapeutics Ltd – Pipeline Products by Top 10 Mechanism of Action, 2016 43

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared